^
    Back
    Association details:
    Biomarker:MYH9-ROS1 fusion
    Cancer:Lung Adenocarcinoma
    Drug:Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Case Rep Oncol
    Title:

    Rare MYH9-ROS1 Fusion Gene-Positive Lung Adenocarcinoma Showing Response to Entrectinib Treatment: A Case Study

    Published date:
    03/31/2022
    Excerpt:
    ...we report a case of MYH9-ROS1 fusion gene-positive lung adenocarcinoma...As the disease worsened, another genetic test was conducted using FoundationOne® CDx, and the MYH9-ROS1 fusion gene was detected. Multiple lung metastases disappeared after the administration of entrectinib; the response persisted up to a year.
    DOI:
    https://doi.org/10.1159/000524071
    Test:
    FoundationOne® CDx